Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings
ConclusionsVenetoclax plus azacitidine was well tolerated and showed high response rates in Japanese patients with acute myeloid leukaemia.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Chemotherapy | Japan Health | Leukemia | Pneumonia | Study | Toxicology